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Abstract 
 
A 37-year-old Malay woman presented with progressive deterioration in vision and was diagnosed with advanced 
proliferative diabetic retinopathy with neovascular glaucoma. Intravitreal ranibizumab injection (an anti-vascular 
endothelial growth factor) was administered prior to vitrectomy. Slit lamp assessment 2 days post-injection revealed 
significant regression of both iris and retinal neovascularisation. This resulted in adequate reduction of intra-ocular 
pressure prior to surgery. In addition, the regression of retinal vessels reduced the risk of intra-operative 
haemorrhage, thus aiding the surgical excision of the fibrovascular membranes. Periodic post-operative assessment 
in the first 3 weeks showed minimal inflammation and no recurrence of vitreous haemorrhage. This case illustrates 
that intravitreal ranibizumab has a role as an adjunct therapy prior to diabetic vitrectomy to significantly reduce the 
risk of intra-ocular haemorrhage.   
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Introduction 
 
Diabetic retinopathy remains the leading cause of 
blindness in the working adult population (1). Chronic 
elevation in serum glucose causes microangiopathy of 
the retinal vasculature characterised by leakage of 
blood constituents, abnormalities in venous calibre, 
microvascular occlusion and retinal ischaemia. As the 
ischaemia progresses, neovascularisation occurs, 
which is termed as proliferative diabetic retinopathy 
(PDR). New vessels can grow on the surface of the 
optic disc, the retinal vessels, the iris or the 
iridocorneal angle. The aqueous drains into the 
trabecular meshwork within the iridocorneal angle; 
development of new vessels here with subsequent 
fibrovascular membranes may impede aqueous 
outflow and lead to neovascular  glaucoma. As new 
vessels grow from the optic disc or retinal vessels, it 
attaches to the posterior vitreous face by means of 
fibrovascular tissue proliferation. Contraction of the 
fibrovascular tissue with or without posterior vitreous 
detachment may lead to tractional retinal detachment, 
a late complication of diabetic retinopathy (2). 
 
The exact pathogenesis of proliferative diabetic 
retinopathy is still uncertain but several animal (3,4) 
and human studies (5,6) suggest that vascular 
endothelial growth factor (VEGF) plays a major role. 
VEGF is an angiogenic factor and a pro-inflammatory 
mediator, leading to neovascularisation and 
breakdown of the blood-retinal barrier (4,7). 
Ranibizumab (Lucentis
TM
, Genentech USA) is a 
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recombinant humanized monoclonal antibody that 
binds to VEGF A and results in reduced proliferation 
of endothelial cells, neovascularisation and vascular 
leakage (8). It has been FDA-approved for use in the 
treatment of neovascularisation due to age-related 
macular degeneration (AMD) and macular oedema 
following retinal vascular occlusion. Following the 
success of anti-VEGF agents in neovascular AMD 
(9), research into the use of anti VEGFs in other 
ischaemic retinal diseases particularly diabetic 
retinopathy have ensued.  
 
There are currently no published reports on the 
adjunctive use of ranibizumab in vitrectomy for 
advanced diabetic retinopathy. We report that pre-
operative ranibizumab is helpful in dramatically 
reducing iris neovascularisation and appears to have 
minimised intra-operative haemorrhage during 
vitrectomy.   
 
Case Report  
 
A 37-year-old Malay woman with a 6-year history of 
Type 2 diabetes mellitus presented with progressive 
visual loss and floaters in the left eye for 2 weeks’ 
duration. Other past medical history included 
hypertension and end-stage renal failure requiring 
haemodialysis. She was previously under the care of 
another ophthalmology centre for bilateral 
proliferative diabetic retinopathy and had 3 sessions 
of pan-retinal photocoagulation (PRP) for both eyes. 
However she had then defaulted treatment for 2 years. 
The visual acuity at presentation was 6/12 in the right 
eye and 6/36 in the left eye with no relative afferent 
pupillary defect. Intra-ocular pressures (IOP) 
measured by Goldmann tonometry in the right and 
left eyes were 18 and 19 mmHg, respectively. 
Anterior segment examination was normal. Contact 
gonioscopy revealed opened irido-corneal angle 
(Grade 4 Shaffer classification) and no 
neovascularisation seen. Fundus examination revealed 
bilateral advanced diabetic eye disease with 
intraretinal haemorrhages, exudates, microaneurysms, 
disc and retinal neovascularisation with fibrous 
proliferation and vitreous haemorrhage. There was 
presence of tractional retinal detachment involving 
the macula with exudative maculopathy in the left 
eye. 
 
Additional bilateral PRP and left macula grid laser 
was given. The new vessels regressed with 
subsequent resolution of the vitreous haemorrhage 
bilaterally. Vision in the right eye improved to 6/9, 
however the left eye vision deteriorated to 2/60 over a 
one month period due to worsening of the tractional 
retinal detachment. Fundus fluorescein angiography 
of the left eye revealed an area of ischaemia 
underlying the tractional retinal detachment inferiorly 
but no macular ischaemia. Patient was scheduled for a 
left trans-pars-plana vitrectomy with fibrovascular 
membrane dissection and excision but surgery was 
delayed due to an infected indwelling venous catheter 
which required hospital admission.  
 
At the subsequent visit one month later during the 
pre-operative assessment, the vision in the left eye 
had further deteriorated to counting fingers. Anterior 
examination revealed florid iris neovascularisation 
(INV) with 270 angle closure (Shaffer Grade 0) in 
the left eye, and the IOP was elevated at 58mmHg. 
Fundus examination of the left eye revealed florid 
disc neovascularisation and tractional retinal 
detachment involving the macula. The IOP was 
lowered by topical and systemic IOP-lowering agents. 
After obtaining informed consent, an intravitreal 
injection of 0.5mg (0.05ml of 10mg/ml) ranibizumab 
was administered to the left eye 3 days prior to 
surgery. Two days after the injection, the INV and 
disc neovascularisation were significantly reduced. 
There was also worsening of the tractional retinal 
detachment. However, there was no conversion to 
rhegmatogenous component. The IOP in the left eye 
was controlled (12 to 15mmHg) and the angle opened 
up to Shaffer Grade 1 on repeat gonioscopy. A trans 
pars plana vitrectomy with membrane segmentation 
and delamination, endolaser and gas tamponade with 
24% sulfurhexafluoride (SF6) was performed on day 
3 post injection. Intra-operatively, there was no 
significant haemorrhage and the fibrovascular tissue 
was successfully removed within an operating time of 
2 hours and 20 minutes thus flattening the retina. 
During the first 3 weeks post-operatively, there was 
minimal intraocular inflammation and the retina 
remained attached with no recurrence of vitreous 
haemorrhage. However, due to recurrence of INV and 
elevated IOP, the left eye vision remained poor at 
2/60.   
 
Discussion 
 
Tractional retinal detachment and neovascular 
glaucoma are late complications of diabetic 
retinopathy and their management remains a 
challenge for ophthalmologists. Panretinal 
photocoagulation has been the standard treatment for 
neovascularisation, whereas vitrectomy with surgical 
relief of the fibrovascular traction has been successful 
in cases of tractional retinal detachment involving the  
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macula (10). However, intra-operative and early post-
operative vitreous haemorrhage particularly in the 
presence of prominent neovascularisation is a major 
concern. Bleeding intra-operatively obscures the 
surgical view and potentially increases the risk of 
complications. Early post-operative haemorrhage can 
worsen inflammation, increase intra-ocular pressure, 
prevent detection of iatrogenic retinal breaks and 
possibly lead to repeat vitrectomy (11). Trials on anti-
VEGF agents used as adjuncts to vitrectomy also 
suggest earlier resolution of vitreous haemorrhage, 
shorter operative time and less intra- and post-
operative bleeding (12). Although, these studies used 
another anti-VEGF agent, bevacizumab (Avastin
TM
, 
Genentech USA), presumably due to its cost, 
ranibizumab was used as it is designed specifically for 
intraocular injection. Some authors report a possible 
risk of worsening of the tractional retinal detachment 
due to contraction of the fibrovascular tissue 
following intravitreal injection of anti-VEGF (13).  
 
In our case, the use of ranibizumab had resulted in 
considerable regression of INV and retinal 
neovascularisation pre-operatively. This seemed to 
have reduced the risk of intra-operative haemorrhage 
both in the anterior and posterior segments, thus 
facilitating the surgical dissection of fibrovascular 
membrane with good surgical view. Furthermore, no 
significant haemorrhage occurred post-operatively. 
The rapid and marked beneficial effects of pre-
operative intravitreal ranibizumab helped in 
controlling the IOP of this patient by reducing angular 
obstruction which has also been observed by previous 
researchers (14). 
 
The emergence of anti-VEGF therapy has 
revolutionised the treatment of ischaemic retinal 
disease particularly neovascular AMD. Its usage in 
diabetic retinopathy seems to be promising however, 
the effect is temporary as in this case and can be 
costly. Panretinal laser photocoagulation along with 
good blood sugar and blood pressure control are still 
the mainstay of treatment. Hence, educating patients 
regarding diabetic retinopathy and its complications, 
and empowering them to take control of their disease 
are still strongly advocated to minimise the 
deleterious effects of diabetic retinopathy. 
 
This case report is the first to illustrate the rapid and 
dramatic regression of INV and reduction in IOP 
following adjunctive intravitreal ranibizumab 
injection for a patient scheduled to undergo 
vitrectomy for advanced proliferative diabetic 
retinopathy. Large randomised controlled trials would 
need to be performed to investigate further the role of 
anti-VEGF in diabetic vitrectomy. 
 
Conclusion 
Pre-operative intravitreal ranibizumab is useful in 
rapidly inducing regression of INV leading to better 
IOP control and improved surgical view in 
subsequent vitrectomy surgery.  
 
References 
 
1. Klein BE. Overview of epidemiologic studies of 
diabetic retinopathy. Ophthalmic Epidemiol 2007 Jul-
Aug;14(4):179-83. 
2. Sun JK, Miller JW, Aiello LP. Albert & Jakobiec’s 
Principles and Practice of Ophthalmology- 
Proliferative Diabetic Retinopathy. Philadelphia: 
Saunders Elsevier, 2008, 1807-9. 
3. Miller JW, Adamis AP, Shima DT, D’Amore PA, 
Moulton RS, O’Reilly MS et al. Vascular endothelial 
growth factor/vascular permeability factor is 
temporally and spatially correlated with ocular 
angiogenesis in a primate model. Am J Pathol 1994 
Sep;145(3):574-84. 
Fig1: Florid anterior segment iris neovascularisation (INV) 
 
Fig 2:  Regression of INV post-intravitreal ranibizumab 
 
70 
 
4. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W et 
al. VEGF-initiated blood-retinal barrier breakdown in 
early diabetes. Invest Ophthalmol Vis Sci 2001 Sep; 
42(10):2408-13. 
5. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. 
Localization of vascular endothelial growth factor in 
human retina and choroid. Arch Ophthal 1996 Aug; 
114(8):971-7. 
6. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel 
HD et al. Vascular endothelial growth factor in ocular 
fluid of patients with diabetic retinopathy and other 
retinal disorders. N Eng J Med 1994 Dec 1; 
331(22):1480-7. 
7. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, 
Adamis AP et al. Pathologic features of vascular 
endothelial growth factor-induced retinopathy in the 
non-human primate. Am J Ophthalmol 2002 Mar; 
133(3):373-85. 
8. Lucentis (Ranibizumab) injection: Prescribing 
information. Website:- www.lucentis.com. Last 
accessed on 28/12/2010. 
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer Ds, Kaiser 
PK et al. Ranibizumab for neovascular age-related 
macular degeneration. N Eng J Med 2006 Oct 5; 
355(4):1419-31. 
10. Newman DK. Surgical management of the late 
complications of proliferative diabetic retinopathy. 
Eye 2010 Mar;24(3):441-9. 
11. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. 
Intravitreal Bevacizumab for prevention of early 
postvitrectomy haemorrhage in diabetic patients. 
Ophthalmology 2009 Oct; 116(10):1943-8. 
12. Nicholson BP, Schachat AP. A review of clinical trials 
of anti-VEGF agents for diabetic retinopathy. Graefes 
Arch Clin Exp Ophthalmol 2010 Jul; 248(7):915-30. 
13. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. 
Bevacizumab pretreatment in vitrectomy with silicone 
oil for severe diabetic retinopathy. Retina 2009 Jun; 
29(6):768-74. 
14. Beutel J, Peters S, Lüke M, Aisenbrey S, Szurman Pet 
al. Bevacizumab as adjuvant for neovascular 
glaucoma. Acta Ophthalmol 2010 Feb; 88(1):103-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
